Skip to main content

Cartesian Therapeutics, Inc.

corporate_fare Company Profile

Cartesian Therapeutics, Inc.

RNAC·NASDAQ·Life Sciences·CIK 0001453687

Cartesian Therapeutics, Inc. is a late clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases. The company utilizes its proprietary technology and manufacturing platform to introduce messenger RNA (mRNA) into cells to achieve a therapeutic effect in patients with various autoimmune conditions. This approach differs from DNA-based therapies as mRNA naturally degrades over time without integrating into the cell's genetic material. Cartesian Therapeutics' cell therapies are designed for repeated dosing, outpatient administration, and do not require pre-treatment chemotherapy, which is often necessary with many conventional cell therapies. Autoimmune diseases encompass over 80 disorders where the immune system mistakenly attacks the body. On November 13, 2023, the company, formerly known as Selecta Biosciences, Inc., completed a merger with Cartesian Therapeutics, Inc. (Old Cartesian), a Delaware corporation, and subsequently changed its corporate name to Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for RNAC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for RNAC spans 10-Q, 8-K, DEF 14A, SCHEDULE 13D/A.

Recent high-impact activity:

  • Cartesian Posts $0.38 Loss, Beats Estimates by 56 Cents as Net Loss Narrows
  • Descartes-08 Retreatment Data Shows 6.6-Point MG-ADL Reduction at Month 12
  • Cartesian Q2 2026: Cash Runway to 2028, Phase 3 AURORA Trial Fuels R&D Growth
  • Cartesian Therapeutics Reports Q2 Results, Cash Runway Into 2028, and Four Clinical Readouts in Next 12 Months
  • Cartesian Partners with WestGene to Advance In Vivo CAR-T Therapies for Autoimmune Diseases

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.8M
Net Income
-$130.3M
Diluted EPS
-$5.02
Op. Cash Flow
-$73.94M
Free Cash Flow
-$79.39M
Operating Income
-$143.41M
Cash & Equivalents
$125.14M
Debt / Equity
0.00×
Net Margin
-46.59×
Shares Outstanding
26.01M sh
Source: 10-K · filed 2026-03-09 · accession 0001453687-26-000064

Short Interest & Short Volume

16.50 days to cover

FINRA reported short interest of 1,916,302 shares in RNAC as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 16.5 days to cover at its recent average daily volume. On November 20, 2026, 66.9% of RNAC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,916,302 shares as of October 30, 2026
Change vs prior period▲ 2.2%
Days to cover16.50 at avg daily volume of 116,169
Daily short volume (FINRA facilities)66.9% of 103,895 shares on November 20, 2026
5-day average short volume67.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with R →
$6.1 -0.65% today
52-week range · as of 2026-08-06 $5.6 – $12.57
Market cap
$187.29M
Volume
279.9K (1.8× avg)
3-mo avg 152K
Live data · 2026-11-22 12:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RNAC - Latest Insights

RNAC
Nov 05, 2026, 9:32 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.86
Real-time Price: $6.10 info
Change: -$0.755 (-11%) info
Market Cap: $187.288M info
RNAC
Sep 29, 2026, 7:31 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.24
Real-time Price: $6.10 info
Change: -$1.14 (-16%) info
Market Cap: $187.288M info
RNAC
Aug 06, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.26
Real-time Price: $6.10 info
Change: -$2.16 (-26%) info
Market Cap: $187.288M info
RNAC
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.26
Real-time Price: $6.10 info
Change: -$2.16 (-26%) info
Market Cap: $187.288M info
RNAC
Jun 09, 2026, 7:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $6.10 info
Change: -$0.300 (-5%) info
Market Cap: $187.288M info
RNAC
Jun 09, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.34
Real-time Price: $6.10 info
Change: -$0.240 (-4%) info
Market Cap: $187.288M info
RNAC
May 26, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $7.24
Real-time Price: $6.10 info
Change: -$1.14 (-16%) info
Market Cap: $187.288M info
RNAC
May 26, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.33
Real-time Price: $6.10 info
Change: -$1.23 (-17%) info
Market Cap: $187.288M info
RNAC
Apr 30, 2026, 7:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $6.10 info
Change: -$0.750 (-11%) info
Market Cap: $187.288M info
RNAC
Apr 30, 2026, 7:04 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.85
Real-time Price: $6.10 info
Change: -$0.750 (-11%) info
Market Cap: $187.288M info
RNAC
Apr 28, 2026, 7:32 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.09
Real-time Price: $6.10 info
Change: -$0.990 (-14%) info
Market Cap: $187.288M info
RNAC
Apr 02, 2026, 5:37 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $6.26
Real-time Price: $6.10 info
Change: -$0.160 (-3%) info
Market Cap: $187.288M info
RNAC
Mar 09, 2026, 7:05 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $6.10 info
Change: -$0.750 (-11%) info
Market Cap: $187.288M info
RNAC
Mar 09, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $6.10 info
Change: -$0.750 (-11%) info
Market Cap: $187.288M info
RNAC
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $6.10 info
Change: -$0.750 (-11%) info
Market Cap: $187.288M info
RNAC
Jan 09, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.30
Real-time Price: $6.10 info
Change: -$2.20 (-27%) info
Market Cap: $187.288M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets